There is a substantial burden, unawareness, and undertreatment of several systemic comorbidities—particularly cardiovascular and psychiatric—in patients with HS.
Acne patients receiving isotretinoin may not need continued testing when experiencing low-grade liver enzyme abnormalities, as most mild elevations do not worsen.
A high prevalence of body dysmorphic disorder (BDD) was observed in patients with acne vulgaris at various dermatology centers in Spain, according to study data published in the Journal of the European Academy of Dermatology and Venereology. Investigators conducted a cross-sectional study at 11 dermatology clinics in Spain. The study enrolled patients age 16 to…
The Food and Drug Administration (FDA) has approved Aklief Cream 0.005% (trifarotene; Galderma) for the topical treatment of acne vulgaris in patients 9 years of age and older.
Degrees of acne severity reflect different biotype and phylotype distributions.
Serum YKL-40 level was significantly elevated in patients with acne, suggesting that it may have a role in acne pathogenesis as well as provide a link between the inflammation and dyslipidemia seen in these patients, a novel study finds.
Researchers identified a greater than twofold crude increase in the 1-year incidence of long-term opioid use among patients with HS compared with controls.
Significant reduction in inflammatory lesions was seen at week 12 at 1.5 mg/kg/day of sarecycline, with statistically significant improvement seen as early as week 3.
The Food and Drug Administration (FDA) has approved Aczone (dapsone; Almirall) Gel 7.5% for the topical treatment of acne vulgaris in patients aged ≥9 years. Previously, the treatment had been indicated for patients 12 years of age and older.
Investigators sought to assess the efficacy of a 30% azelaic acid peel on acne lesions.